CRISM Therapeutics Corporation (A7L.F)

0.0040 0.0000 (0.00%) At close: 09:03AM CEST

CRISM Therapeutics Corporation

Kingston Chambers
PO Box 173
Road Town
British Virgin Islands

Sector(s): 
Industry: 
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Robin Jay Young	CEO, Secretary & Executive Director	290.41k	N/A	1955
Mr. Ae Jack Swanson	Chief Operating Officer	N/A	N/A	1938

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

Corporate Governance

CRISM Therapeutics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.